MOTS-c Boosts Metabolism in Stem Cells But Paradoxically Worsens Their Repair Function
A surprising study finds the longevity-linked peptide MOTS-c activates AMPK signaling in fat-derived stem cells but triggers senescence and blunts tissue repair.
Summary
Researchers tested whether MOTS-c, a mitochondria-derived peptide known to improve metabolism, could rescue stem cells impaired by obesity. Mesenchymal stromal cells (MSCs) from obese donors showed lower baseline MOTS-c and dysfunctional repair capacity. Supplementing MOTS-c restored intracellular levels and activated the metabolic sensor AMPK, but unexpectedly reduced cell proliferation, increased senescence markers (p16, p21), and elevated inflammatory TNF-α. In mice with kidney artery stenosis, MOTS-c-pretreated obese MSCs failed to improve renal perfusion, oxygenation, or fibrosis — and even blunted the repair capacity of healthy lean MSCs. The findings reveal a critical dissociation between metabolic activation and functional stem cell potency, cautioning against assuming that restoring mitochondrial signaling automatically rescues cell therapy effectiveness.
Detailed Summary
Stem cell therapy using mesenchymal stromal cells (MSCs) holds significant promise for regenerative medicine, but obesity impairs MSC function, limiting their usefulness for autologous therapies. Obese patients' adipose-derived MSCs are known to express higher levels of senescence and inflammatory genes and fail to repair injured tissues. Researchers at Mayo Clinic hypothesized that MOTS-c — a mitochondrial-encoded peptide with established metabolic benefits — could rescue these dysfunctional cells by restoring mitochondrial signaling.
The study isolated subcutaneous adipose MSCs from six obese (BMI ≥ 30) and six lean (BMI < 30) donors matched for age and sex. Baseline MOTS-c protein expression was significantly lower in obese MSCs. In vitro, 48-hour co-incubation with 10 µM exogenous MOTS-c successfully restored intracellular MOTS-c levels and activated AMPK signaling in obese MSCs — a canonical metabolic improvement. However, despite this biochemical rescue, MOTS-c treatment reduced MSC proliferation, upregulated senescence-associated genes p16 and p21, and elevated pro-inflammatory TNF-α expression in both obese and lean MSCs. Antioxidant gene expression (SOD1, GPX, CAT) and cell adhesion were not significantly altered.
The in vivo phase tested whether MOTS-c pretreatment could enhance the reparative potency of obese MSCs in a well-validated murine renal artery stenosis (RAS) model. After surgical cuff placement on the right renal artery, mice received aortic injections of lean or obese MSCs — pretreated or untreated with MOTS-c — and were assessed two weeks later by MRI. Untreated lean MSCs provided meaningful improvements in renal perfusion, oxygenation, and fibrosis in stenotic kidneys, consistent with prior literature. Obese MSCs provided minimal benefit, as expected. Critically, MOTS-c pretreatment failed to rescue obese MSC repair function across all renal endpoints (perfusion, BOLD-MRI oxygenation, tubular injury score, interstitial fibrosis). More strikingly, MOTS-c pretreatment also impaired the already-functional lean MSCs, blunting their reparative efficacy in vivo.
These findings introduce an important conceptual nuance: metabolic activation and functional stemness are dissociable. Restoring AMPK signaling via MOTS-c is insufficient — and potentially detrimental — for stem cell repair function. The induction of senescence markers alongside metabolic activation suggests that MOTS-c may engage stress-response programs in MSCs that compromise their therapeutic identity. This context-dependent behavior of mitochondrial-derived peptides in stem cells has not been previously described and warrants further mechanistic investigation.
The study is limited by a small human donor cohort (n=6/group) and a single MOTS-c dose and duration. Longer-term or dose-ranging studies, as well as exploration of MSCs from other tissue compartments, are needed before broader conclusions can be drawn about MOTS-c's role in stem cell biology.
Key Findings
- Obese adipose MSCs have significantly lower baseline MOTS-c protein expression than lean MSCs.
- Exogenous MOTS-c restores AMPK signaling but reduces MSC proliferation and raises senescence genes p16 and p21.
- MOTS-c increases pro-inflammatory TNF-α expression in both obese and lean MSCs in vitro.
- In a mouse renal artery stenosis model, MOTS-c pretreatment failed to rescue obese MSC repair function across all kidney endpoints.
- MOTS-c pretreatment paradoxically blunted the reparative efficacy of otherwise functional lean MSCs in vivo.
Methodology
Human adipose MSCs from 6 obese and 6 lean donors were treated with 10 µM MOTS-c for 48 hours and assessed for proliferation, adhesion, gene expression, and AMPK-pathway signaling in vitro. In vivo efficacy was tested in a murine renal artery stenosis model (n=6/group) using aortic MSC injection, with renal outcomes measured by MRI and histology two weeks post-infusion.
Study Limitations
The human donor cohort was small (n=6 per group), limiting statistical power and generalizability. Only a single MOTS-c dose (10 µM) and treatment duration (48 h) were tested, leaving dose-response and timing effects unexplored. MSCs were derived solely from subcutaneous abdominal fat, so findings may not apply to MSCs from other tissue sources.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: